Article Versions Notes

Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y, Imai Y, Ohkawa K, Miyazaki M, Tanaka S, et al. Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers. 2022; 14(4):883. https://doi.org/10.3390/cancers14040883

Myojin, Yuta, Takahiro Kodama, Ryotaro Sakamori, Kazuki Maesaka, Takayuki Matsumae, Yoshiyuki Sawai, Yasuharu Imai, Kazuyoshi Ohkawa, Masanori Miyazaki, Satoshi Tanaka, and et al. 2022. "Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy" Cancers 14, no. 4: 883. https://doi.org/10.3390/cancers14040883

Myojin, Y., Kodama, T., Sakamori, R., Maesaka, K., Matsumae, T., Sawai, Y., Imai, Y., Ohkawa, K., Miyazaki, M., Tanaka, S., Mita, E., Tawara, S., Yakushijin, T., Nozaki, Y., Hagiwara, H., Tahata, Y., Yamada, R., Hikita, H., Tatsumi, T., & Takehara, T. (2022). Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers, 14(4), 883. https://doi.org/10.3390/cancers14040883